Race Oncology (ASX:RAC) has received human ethics approval to commence its HARNESS-1 Phase 1a/b clinical trial evaluating RC220, its next-generation formulation of bisantrene, in combination with AstraZeneca's TAGRISSO (osimertinib) for patients with EGFR-mutated non-small cell lung cancer. …
Race Oncology secures human ethics approval for lung cancer trial of RC220
November 26, 2025 Australian Biotech
Latest Video
New Stories
-
LifeSciences Australia honours outstanding professionals at MTP Sector Awards 2026
June 12, 2026 - - Latest News -
'The changes could cause irreversible damage to our vibrant and world-leading biotech, medtech and health tech sector'
June 12, 2026 - - Australian Biotech -
The opportunity to change the conversation, the negotiating dynamic, and take some control
June 12, 2026 - - Latest News -
State and Territory ministers warn against centralising NDIS power
June 12, 2026 - - Latest News -
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech